logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon Pharmaceuticals applies for Phase 2b/3 study on Ifenprodil in Australia

Algernon Pharmaceuticals ( CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau checked in with Steve Darling from Proactive to provide an update on the company as they seek approval in Australia for a Phase 2b/3 study of their repurposed drug Ifenprodil for coronavirus. The company already has approval in Canada and will soon apply in the United States.  

Moreau telling Proactive when they get approval it will be a Phase 2b study of 100 patients between Australia, Canada and the United States. Then with positive data, the study will move directly into a Phase 3 trial. 

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.255 CAD

CSE:AGN
Market: CSE
Market Cap: $22.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Filta Group Holdings CEO reveals recent trading update highlights

Filta Group Holdings PLC (LON:FLTA) CEO James Sayers tells Proactive the commercial kitchens service provider has seen a gradual improvement in activity recently as coronavirus lockdown restrictions ease. Sayers says turnover in May was 14% higher than in April while June’s topped May’s by...

5 hours, 39 minutes ago

2 min read